BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 32826479)

  • 1. Cutaneous and systemic connections in lupus.
    Maz MP; Michelle Kahlenberg J
    Curr Opin Rheumatol; 2020 Nov; 32(6):583-589. PubMed ID: 32826479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenetics of cutaneous lupus erythematosus.
    Hersh AO; Arkin LM; Prahalad S
    Curr Opin Pediatr; 2016 Aug; 28(4):470-5. PubMed ID: 27386968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological therapies in the treatment of cutaneous lupus erythematosus.
    Presto JK; Hejazi EZ; Werth VP
    Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus.
    Cho YM; Furie R
    Immunotherapy; 2024 Jan; 16(1):15-20. PubMed ID: 37877249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
    Zhang YP; Wu J; Han YF; Shi ZR; Wang L
    Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Lupus Erythematosus: Progress and Challenges.
    Petty AJ; Floyd L; Henderson C; Nicholas MW
    Curr Allergy Asthma Rep; 2020 Apr; 20(5):12. PubMed ID: 32248318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients.
    Chanprapaph K; Tubtieng I; Pratumchat N; Thadanipon K; Rattanakaemakorn P; Suchonwanit P
    Lupus; 2021 Apr; 30(5):785-794. PubMed ID: 33554715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice.
    Patel J; Borucki R; Werth VP
    Curr Rheumatol Rep; 2020 Aug; 22(10):69. PubMed ID: 32845411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
    Stannard JN; Kahlenberg JM
    Curr Opin Rheumatol; 2016 Sep; 28(5):453-9. PubMed ID: 27270345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of neutrophils in cutaneous lupus erythematosus.
    Yamamoto T
    J Dermatol; 2024 Feb; 51(2):180-184. PubMed ID: 38009863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update on the Pathogenesis of Skin Damage in Lupus.
    Li Q; Wu H; Zhou S; Zhao M; Lu Q
    Curr Rheumatol Rep; 2020 May; 22(5):16. PubMed ID: 32399815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in cytokines in cutaneous and systemic lupus erythematosus.
    Mikita N; Ikeda T; Ishiguro M; Furukawa F
    J Dermatol; 2011 Sep; 38(9):839-49. PubMed ID: 21767292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
    Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
    Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging biologic therapies for systemic lupus erythematosus.
    Kato H; Kahlenberg JM
    Curr Opin Rheumatol; 2024 May; 36(3):169-175. PubMed ID: 38299618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials.
    Lim D; Kleitsch J; Werth VP
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):257-273. PubMed ID: 37860982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications.
    Chlebus E; Wolska H; Blaszczyk M; Jablonska S
    J Am Acad Dermatol; 1998 Mar; 38(3):405-12. PubMed ID: 9520021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus.
    Cho SK; Vazquez T; Werth VP
    Expert Opin Investig Drugs; 2023 May; 32(5):345-353. PubMed ID: 37148249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.
    Udompanich S; Chanprapaph K; Suchonwanit P
    Am J Clin Dermatol; 2018 Oct; 19(5):679-694. PubMed ID: 29948959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.